EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

The 2026 European Academy of Dermatology and Venereology (EADV) Congress, held September 30 to October 3 in Vienna, Austria, brought a dense dermatology program spanning established therapies, late-breaking pipeline data, and emerging mechanisms well outside the current biologic landscape. Atopic dermatitis featured prominently across the week, with new long-term durability data for approved agents, phase 3 results for a second IL-4Rα antibody, and early readouts for 2 novel mechanisms — one a first-in-class oral option and the other the first public data for a trispecific antibody in the disease.

Here are 5 atopic dermatitis headlines from EADV 2026.

1. RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year

One-year interim results from the real-world RELIEVE-AD-PEDs study showed 73.8% of adolescents with moderate to severe atopic dermatitis reported controlled disease on the Atopic Dermatitis Control Tool (ADCT) after 12 months on dupilumab, up from 12.1% at baseline, with controlled disease already reaching 57.9% as early as 2 weeks after initiation. The proportion reporting more than 2 flares in the prior 4 weeks fell from 51.3% to 15.1%, and 88.1% of patients remained on therapy at the 12-month survey. April Armstrong, MD, MPH, of the University of California Los Angeles discussed the data with HCPLive at the congress.

2. Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD

Phase 2 data for tilrekimig (PF-07275315), an investigational trispecific antibody simultaneously targeting IL-4, IL-13, and TSLP, showed EASI-75 rates of 48% to 63% across all doses at week 16 in biologic-naive adults with moderate to severe atopic dermatitis, compared with 9% to 20% with placebo — marking the first public controlled efficacy data for any bispecific or trispecific antibody in the disease. Pfizer has since initiated phase 3 development, including a trial with dupilumab as an active comparator. HCPLive sat down with lead author Eric Simpson, MD, MCR, of Oregon Health & Science University, for a video interview on the findings, the vIGA gap, and the absence of a conjunctivitis signal.

3. EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

Telikibart (GR1802), a fully human anti-IL-4Rα monoclonal antibody with an engineered Fc region designed to eliminate antibody-dependent cell-mediated cytotoxicity, met both coprimary endpoints in a phase 3 trial, with 69.6% of patients achieving EASI-75 at week 16 versus 22.5% with placebo and IGA 0/1 in 33.1% versus 6.6%. Responses deepened substantially during the open-label maintenance phase, with EASI-75 exceeding 94% by week 52 in both the continuous-treatment and placebo-crossover groups. The data were presented as a late-breaking abstract at the congress.

4. First-in-Class Oral ENV-294 Evaluated in Atopic Dermatitis, With Leon Kircik, MD

ENV-294, a first-in-class oral Rac2 modulator developed by Enveda Biosciences, produced a 68% reduction in EASI scores at day 28 in a small phase 1b open-label study in moderate to severe atopic dermatitis — with improvement deepening to 85% by day 42, 2 weeks after the final dose. The continued response after treatment ended and the absence of treatment-related adverse events beyond a single mild headache were highlighted as key observations ahead of an ongoing phase 2 randomized controlled trial. HCPLive spoke with investigator Leon Kircik, MD, in a video interview about the mechanism, the early efficacy signal, and what a non-JAK oral option could mean for the field.

5. Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

New long-term extension data from the ARCADIA and OLYMPIA trials showed nemolizumab sustained skin clearance and itch relief for up to 3 years in patients with atopic dermatitis and prurigo nodularis, adding to the durability picture for the approved IL-31 receptor antagonist. HCPLive spoke with Matthias Augustin, MD, PhD, in a video interview on the 3-year findings and their implications for long-term management.